LIP
ELVN icon

Lighthouse Investment Partners’s Enliven Therapeutics ELVN Stock Holding History

Lighthouse Investment Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
20,000
-55,000
-73% -$2.33M 0.03% 472
2026
Q1 		$2.94M Buy
75,000
+10,000
+15% +$277K 0.1% 268
2025
Q4 		$1M Buy
+65,000
New +$1.29M 0.03% 479

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Lighthouse Investment Partners's ELVN Position: Q2 2026 in Review

Lighthouse Investment Partners reduced its Enliven Therapeutics (ELVN) stake by 73% in Q2 2026, selling an estimated $2.33M and leaving 20,000 shares worth $1.01M. The position accounts for 0.03% of the portfolio, ranked #472.

Lighthouse Investment Partners first reported a position in ELVN in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.94M in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Lighthouse Investment Partners held 20,000 shares of Enliven Therapeutics worth $1.01M as of Q2 2026.
  • Lighthouse Investment Partners sold 55,000 Enliven Therapeutics shares in Q2 2026, an estimated $2.33M.
  • Enliven Therapeutics made up 0.03% of Lighthouse Investment Partners's portfolio in Q2 2026, its #472 holding.
  • Lighthouse Investment Partners first reported a position in Enliven Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Lighthouse Investment Partners's Enliven Therapeutics position peaked at $2.94M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Lighthouse Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.